3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow ASP8232: new trials by email Literature Review of ASP8232 trials Research Report on ASP8232
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease ASP8232, Placebo - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Completed | Astellas Pharma Europe B.V. | 125 | 2015-03-17 | 2024-10-31 |
| A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) ASP8232, ranibizumab, Placebo - Diabetes Mellitus, Diabetic Macular Edema | Phase 2 | Completed | Astellas Pharma Europe B.V. | 96 | 2015-01-12 | 2024-10-31 |
| A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease ASP8232, Placebo - Healthy Subjects, Pharmacokinetics of ASP8232 | Phase 1 / Phase 2 | Completed | Astellas Pharma Europe B.V. | 55 | 2013-09-16 | 2024-10-31 |
Diabetes Mellitus, Type 2 (2) · Renal Insufficiency, Chronic (2) · Diabetes Mellitus (1)
Astellas Pharma Europe B.V. (3)
Bulgaria (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Italy (1) · Moldova (1) · Netherlands (1) · Poland (1) · Romania (1) · Spain (1) · United Kingdom (1) · United States (1)
2014 (1)